Literature DB >> 30148213

Factors Influencing Acute Stroke Thrombolytic Treatments in Hispanics In the San Diego Region.

P M Chen1, D T Nguyen1, J P Ho1, M Pirastehfar1, R Narula1, K Rapp1, K Agrawal1, B Huisa1, R Modir1, D Meyer1, T Hemmen1, C Kidwell2, B C Meyer1.   

Abstract

BACKGROUND: Since the introduction of recombinant tissue plasminogen activator (rt-PA) for acute ischemic stroke, rt-PA rate and number of stroke centers have increased. Despite this, studies have shown racial and ethnic disparities in stroke care especially in Black and Hispanic populations. What factors are related to the administration of rt-PA within the Hispanic population has to date been unclear.
METHODS: We performed a retrospective review of IRB approved, prospectively collected data from the UC San Diego Stroke Registry from 7/2004-7/2016. Patients were included based on the primary diagnosis of Transient Ischemic Attack or Ischemic Stroke. Hispanic vs non-Hispanic patients were compared to assess for overall rt-PA treatment rates and process of care intervals. For the Hispanic cohort itself, demographics and NIHSS scores were assessed to determine why some Hispanics received rt-PA while others were not.
RESULTS: Overall, 1489 patients (300 Hispanic vs. 1189 non-Hispanic) were included. Comparing Hispanics to non-Hispanics, there was no difference in rt-PA rate (35.3% vs. 33.1%; p=0.49). In rt-PA treated patients, "onset to arrival" interval was higher in Hispanics (1.03 vs. 0.88 hours; p=0.04), while the "arrival to treatment" interval was not different (1.13 vs. 1.02 hours; p=0.07). When looking at Hispanic patients only, there was no difference in baseline characteristics except for initial NIHSS in treated vs. non-treated patients (13.27 vs. 7.24; p<.001).
CONCLUSION: Our analyses sought to determine the factors important to administration of rt-PA to Hispanic patients. These findings highlight the need for strategies to improve recognition and presentation pathways for Hispanics.

Entities:  

Keywords:  Ethnic Disparities; Hispanic; Regional Stroke Differences; Stroke; TPA

Year:  2018        PMID: 30148213      PMCID: PMC6103626     

Source DB:  PubMed          Journal:  Austin J Cerebrovasc Dis Stroke        ISSN: 2381-9103


  13 in total

1.  Are racial disparities in stroke care still prevalent in certified stroke centers?

Authors:  Pratik Bhattacharya; Flicia Mada; Leeza Salowich-Palm; Sabrina Hinton; Scott Millis; Sam R Watson; Seemant Chaturvedi; Kumar Rajamani
Journal:  J Stroke Cerebrovasc Dis       Date:  2011-11-10       Impact factor: 2.136

2.  Racial disparities in tissue plasminogen activator treatment rate for stroke: a population-based study.

Authors:  Amie W Hsia; Dorothy F Edwards; Lewis B Morgenstern; Jeffrey J Wing; Nina C Brown; Regina Coles; Sarah Loftin; Andrea Wein; Sara S Koslosky; Sabiha Fatima; Brisa N Sánchez; Ali Fokar; M Chris Gibbons; Nawar Shara; Annapurni Jayam-Trouth; Chelsea S Kidwell
Journal:  Stroke       Date:  2011-06-30       Impact factor: 7.914

3.  Racial-ethnic disparities in stroke care: the American experience: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Salvador Cruz-Flores; Alejandro Rabinstein; Jose Biller; Mitchell S V Elkind; Patrick Griffith; Philip B Gorelick; George Howard; Enrique C Leira; Lewis B Morgenstern; Bruce Ovbiagele; Eric Peterson; Wayne Rosamond; Brian Trimble; Amy L Valderrama
Journal:  Stroke       Date:  2011-05-26       Impact factor: 7.914

4.  Racial and ethnic disparities in the use of intravenous recombinant tissue plasminogen activator and outcomes for acute ischemic stroke.

Authors:  Deena M Nasr; Waleed Brinjikji; Harry J Cloft; Alejandro A Rabinstein
Journal:  J Stroke Cerebrovasc Dis       Date:  2011-12-11       Impact factor: 2.136

5.  Race/ethnicity, quality of care, and outcomes in ischemic stroke.

Authors:  Lee H Schwamm; Mathew J Reeves; Wenqin Pan; Eric E Smith; Michael R Frankel; DaiWai Olson; Xin Zhao; Eric Peterson; Gregg C Fonarow
Journal:  Circulation       Date:  2010-03-22       Impact factor: 29.690

6.  Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.

Authors:  Lee H Schwamm; Syed F Ali; Mathew J Reeves; Eric E Smith; Jeffrey L Saver; Steven Messe; Deepak L Bhatt; Maria V Grau-Sepulveda; Eric D Peterson; Gregg C Fonarow
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-09-01

7.  Racial and gender differences in stroke severity, outcomes, and treatment in patients with acute ischemic stroke.

Authors:  Amelia K Boehme; James E Siegler; Michael T Mullen; Karen C Albright; Michael J Lyerly; Dominique J Monlezun; Erica M Jones; Rikki Tanner; Nicole R Gonzales; T Mark Beasley; James C Grotta; Sean I Savitz; Sheryl Martin-Schild
Journal:  J Stroke Cerebrovasc Dis       Date:  2014-01-25       Impact factor: 2.136

8.  National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate.

Authors:  Dawn Kleindorfer; Christopher J Lindsell; Lawrence Brass; Walter Koroshetz; Joseph P Broderick
Journal:  Stroke       Date:  2008-01-31       Impact factor: 7.914

9.  Association of Hispanic ethnicity with acute ischemic stroke care processes and outcomes.

Authors:  William P Neil; Rema Raman; Thomas M Hemmen; Karin Ernstrom; Brett C Meyer; Dawn M Meyer; Bruce Ovbiagele
Journal:  Ethn Dis       Date:  2015       Impact factor: 2.006

10.  Racial Disparities in Intravenous Recombinant Tissue Plasminogen Activator Use Persist at Primary Stroke Centers.

Authors:  Hugo J Aparicio; Brendan G Carr; Scott E Kasner; Michael J Kallan; Karen C Albright; Dawn O Kleindorfer; Michael T Mullen
Journal:  J Am Heart Assoc       Date:  2015-10-14       Impact factor: 5.501

View more
  1 in total

1.  Time Window for Acute Stroke Management: A Cross-Sectional Study Among Community Healthcare Practitioners in Primary Care.

Authors:  Huajie Yang; Xiang Huang; Chunyu Yang; Sufen Zhu; Xiaoyi Chen; Man Zhang; Xiao Yu; Harry H X Wang
Journal:  Int J Gen Med       Date:  2022-04-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.